Abstract: This disclosure is directed to automated processes for attesting to trustworthiness of a host considered for connection to a data center network. The attestation process is performed in two attestation phases. In the first phase, attestation is performed on a smart network interface controller (“SNIC”) connected to an internal bus of the host using a first trusted platform module (“TPM”) of the SNIC. In the second phase, attestation is performed on the host by the SNIC using a second TPM connected to the internal bus of the host in response to a determination that the SNIC is trustworthy. The host is connected to the data center network in response to a determination by the SNIC that the host is trustworthy.

Abstract: Use of immune checkpoint inhibitors in combination with anti-aging drugs in tumor treatment and tumor treatment products are disclosed, which provides a new drug and treatment strategy for effective treatment of tumors. The therapeutic effect of the provided treatment of ICIs in combination with the anti-aging drug is superior to that of the current treatment of ICIs treatment alone, and ICIs in combination with chemotherapy, etc. In the action process of ICIs in combination with the anti-aging drug, aging cells can be selectively removed, the aging state of an immune system thus is reversed. Accordingly, the inhibitory effect of tumor on the immune micro-environment is reduced, thus improving the treatment effect on various solid tumors. Based on the use or product provided by the present invention, new strategies and new ideas can be provided for further improving the clinical efficacy and prognosis of the solid tumors.